Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2015. The unaudited financial statements are consolidated and reflect the reverse acquisition completed in September 2014; historical statements are those of Citius Pharmaceuticals, LLC, the accounting acquirer.
Business context
Citius develops formulations intended to improve delivery and compliance of approved drugs. Suprenza, its approved and marketed product, is licensed to Prenzamax for U.S. commercialization. Citius reported no revenue or royalty income because the agreement’s payment conditions had not been met. The company was developing a product for hemorrhoid treatment.
Financial highlights
| Metric | Three months ended March 31, 2015 | Six months ended March 31, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $282,238 | $759,361 |
| General and administrative | $217,911 | $510,929 |
| Stock-based compensation | $108,765 | $217,529 |
| Operating loss | $(608,914) | $(1,487,819) |
| Net loss | $(345,268) | $(1,168,976) |
| Basic and diluted loss per share | $(0.01) | $(0.04) |
There was no meaningful operating margin because the company had no revenue. A $323,688 six-month gain from revaluing warrant liabilities partly offset operating losses; it was a noncash accounting gain.
- Cash and cash equivalents: $760,355 at March 31, 2015, down from $1,552,060 at September 30, 2014.
- Cash flow: $1,051,705 used in operations and $260,000 provided by financing during the six months. Cash declined by $791,705.
- Liquidity and capital: Working capital deficit of $923,426; total current liabilities of $1,683,781; stockholders’ deficit of $918,025.
- Debt and warrant liability: Promissory notes were zero at quarter-end after $600,000 principal and $33,333 accrued interest converted into 1,055,554 shares. Derivative warrant liability was $1,245,231.
- Equity financing: The March 2015 placement raised $270,000 gross ($260,000 net) through 500,000 units. A further $454,500 gross was raised in April, after quarter-end.
Changes versus prior comparable periods
For the six months, net loss increased to $1,168,976 from $624,693 in 2014. Operating expenses rose to $1,487,819 from $549,022, including higher R&D spending, public-company and consulting costs, and new stock-based compensation. The increase in R&D was primarily attributed to development of the hemorrhoid product. Lower interest expense after debt conversions and the warrant revaluation gain partly offset the higher expenses. Six-month operating cash use increased to $1,051,705 from $554,344.
Outlook, risks and notable matters
- Management stated that available funds were expected to support operations for the next nine months and that additional capital would be needed. The filing warns that there is no assurance financing will be obtained on acceptable terms or in time.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring losses, operating cash outflows, a working capital deficit and limited capital.
- Key risks include financing needs, clinical-trial success, regulatory approvals, product commercialization, and dependence on personnel, suppliers and strategic partners.
- Warrants with down-round provisions are carried as a Level 3 fair-value liability. Valuation depends on management estimates, including volatility, and changes affect reported earnings.
- Disclosure controls and procedures were deemed ineffective as of March 31, 2015. Material weaknesses included no independent board or audit committee, inadequate documented procedures, reliance on consultants for financial reporting, and limited segregation of duties.
- No legal proceedings or changes to the risk factors previously reported were disclosed. Management reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Cash runway and whether additional financing is available and sufficient to fund operations and clinical development.
- Progress, costs and funding needs for the hemorrhoid product and other development programs.
- Whether Suprenza generates partner profitability, reimbursements or royalty payments for Citius.
- Potential dilution and earnings volatility from outstanding warrants, their down-round provisions and fair-value assumptions.
- Remediation of the disclosed internal-control weaknesses; also note the filing reported 32,422,507 common shares outstanding as of May 8, 2015, versus 31,580,840 at March 31.